Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 77 от 222

Recruiting

Optimizing Timing of Cesarean Delivery Consent on Labor and Delivery

Pregnancy Informed Consent

Nationally, 32.1% of pregnant patients deliver via cesarean delivery, including both patients who undergo a planned cesarean delivery and patients who intend to undergo vaginal delivery and are recommended to deliver via cesarean delivery. The investigators aim to understand how to optimize the patient experience for patients who present to the hospital intending to deliver vaginally but are recommended to deliver via cesarean delivery (an unplanned cesarean delivery). Practices regarding timing of informed consent for possible cesarean delivery vary widely across hospitals in the United States; some institutions will consent every patient on admission to the hospital for possible cesarean delivery, whereas some institutions consent patients for possible cesarean delivery only if a patient's clinical course suggests cesarean delivery may be indicated. This study aims to determine optimal timing for consent for possible cesarean delivery by randomizing patients to either be consented for possible cesarean delivery on admission to the hospital or if it appears to be clinically indicated. This study will only assess altered timing of a surgical consent process and will not impact the clinical care participants receive. After delivery, participants will share their experiences with the consent process and with their overall childbirth experience.

Начало: 27.08.2025 Край: 01.05.2027 Възраст: от 18 г.

United States Duke University NCT07117708

Recruiting

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

Parkinson Disease

The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.

Начало: 27.08.2025 Край: 01.02.2028 Възраст: от 18 г.

Germany Bial - Portela C S.A. NCT07145190

Recruiting Phase 1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Renal Cell Carcinoma Urothelial Carcinoma Castration-resistant Prostate Cancer

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Начало: 27.08.2025 Край: 01.02.2029 Възраст: от 18 г.

United States Deciphera Pharmaceuticals, LLC NCT06966024

Recruiting Phase 1

3D1015 Injection for Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer, mCRPC

This open-label clinical study investigates 3D1015 Injection (Lu 177-PSMA-3D1015) in adult males with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Participants will receive intravenous infusions of 3D1015, with treatment regimens dynamically individualized to optimize patient safety and outcomes. The primary objectives are to assess the safety, tolerability, and dosimetry of the injection. Secondary objectives include evaluating preliminary anti-tumor efficacy and exploring the optimal dosing regimen.

Начало: 27.08.2025 Край: 31.12.2027 Възраст: от 18 г.

China Chunjing Yu NCT07537010

Recruiting Phase 3

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Metastatic Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.

Начало: 27.08.2025 Край: 22.04.2028 Възраст: от 18 г.

Argentina, Austria, Brazil +12 BeOne Medicines NCT07043400

Recruiting Phase 1

A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755

Healthy

This is a Phase 1, open-label, randomized, single-center study to evaluate the effect of food and a proton pump inhibitor (PPI) on the pharmacokinetics (PK) of VRN110755 in healthy adult participants. The primary aim of this study is to assess the impact of food and rabeprazole co-administration on the systemic exposure of VRN110755. Safety and tolerability will also be evaluated.

Начало: 27.08.2025 Край: 30.01.2026 Възраст: 18–65 г. Treatment

Australia Voronoi, Inc NCT07141381

Recruiting Phase 1/2

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Advanced Solid Tumor

The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with pumitamig (also known as BNT327 or PM8002) as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.

Начало: 27.08.2025 Край: 01.08.2028 Възраст: от 18 г. Treatment

Australia, China BioNTech SE NCT07147348

Recruiting

Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

Allergic Asthma Thunderstorm Asthma Seasonal Allergic Rhinitis Grass Pollen Allergy +2

Thunderstorm asthma is a recurring public health emergency in South-Eastern Australia which occurs in springtime. The major identified risk factors for thunderstorm asthma is hay fever and allergy to ryegrass pollen. The goal of the CARISTA study is to identify the risk of springtime allergic and thunderstorm asthma in allergic adults living in South-Eastern Australia. To do this the investigators will recruit 530 people who have hay fever and test them for allergy to ryegrass pollen and undertake simple lung function testing. The investigators will ask study participants to complete a customised symptom tracker over the springtime pollen season for 2 consecutive years. The outcome the investigators are looking for is an asthma exacerbation or worsening asthma symptoms. This study will enable the investigators to identify indicators (biomarkers) of severe and moderate asthma exacerbations in order to identify those at risk of thunderstorm and seasonal asthma so protective treatments and strategies can be advised.

Начало: 27.08.2025 Край: 31.12.2030 Възраст: 18–70 г. Diagnostic

Australia University of Melbourne NCT07055542

Recruiting Phase 3

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Invasive Mold Infections

The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections. The study is looking for patients who have been diagnosed with invasive mold infections. The maximum study duration will be approximately 8 months, including a target study treatment duration of 84 days which can be extended up to 180 days and follow-up period. The patient will be assigned to one of two treatment cohorts: Cohort A (primary therapy): Patients will receive either the study drug or institutional standard of care antifungal treatment. Cohort B (salvage treatment; i.e. treatment given after patients did not respond to previous treatments or did not tolerate them): Patients will receive the study drug The primary aim is to compare the all cause mortality with a fixed threshold at Day 42.

Начало: 26.08.2025 Край: 01.02.2028 Възраст: от 18 г. Treatment

Australia, Austria, Belgium +9 Basilea Pharmaceutica NCT06925321

Recruiting Phase 2

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Acute Gouty Arthritis Gout Flare Gout Flares Acute Gout Flare

A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.

Начало: 26.08.2025 Край: 01.06.2026 Възраст: 18–70 г. Treatment

Australia, China, United States Atom Therapeutics Co., Ltd NCT07145229

Recruiting Phase 1

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

Healthy Volunteers

This is a Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants.

Начало: 26.08.2025 Край: 01.09.2026 Възраст: 18–65 г. Treatment

Australia Suzhou Ribo Life Science Co. Ltd. NCT07042594

Recruiting Phase 2

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Atoptic Dermatitis

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Начало: 26.08.2025 Край: 01.07.2026 Възраст: от 18 г. Treatment

New Zealand, United States Evommune, Inc. NCT07150845

Recruiting Phase 1

A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors

Advanced Solid Tumor Solid Tumors MTAP-deleted Solid Tumors MTAP Deletion

This is a first-in-human clinical study of PEP08, a novel cancer therapy being evaluated both as monotherapy and in combination with other treatments in patients with advanced or metastatic solid tumors harboring MTAP deletion. The study will be conducted in three parts, with Part 1 currently open for enrollment. The primary objectives of the study are to: * Evaluate the safety and tolerability of PEP08, PK and PD * Determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) * Assess preliminary signs of anti-tumor activity of PEP08 Key study questions include: * What is the recommended dose of PEP08 for further development? * Wht is the tolerable dose of PEP08 when administered alone or in combination? * Does PEP08 show early evidence of clinical activity in patients with MTAP-deleted tumors? Participants in the study will: * Receive PEP08 alone or in combination with another anti-cancer agent, depending on the study part * Attend regular clinic visits for treatment administration, laboratory assessments, and tumor evaluations * Be enrolled in one of the following study phases over time: * \- Part 1: Monotherapy dose escalation (currently enrolling). * \- Parts 2 and 3 (monotherapy extension and combination therapy) will be activated in future protocol amendments.

Начало: 26.08.2025 Край: 01.03.2028 Възраст: от 18 г. Treatment

Australia, Taiwan PharmaEngine NCT06973863

Recruiting Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

PIK3CA Mutation HER2- Negative Breast Cancer Hormone Receptor Positive Tumor Breast Cancer +2

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Начало: 26.08.2025 Край: 31.12.2031 Възраст: от 18 г. Treatment

Australia, Belgium, Brazil +14 Relay Therapeutics, Inc. NCT06982521

Recruiting

Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients

Cataract Retinitis Pigmentosa (RP)

This is a self-controlled randomized clinical trial to investigate the effect of capsular tension ring (CTR) implantation on intraocular lens (IOL) position in cataract patients with retinitis pigmentosa(RP). Each patient will receive CTR implantation in one eye, with the fellow eye serving as control. Postoperative outcomes, including visual acuity, IOL position, and postoperative complications will be compared between eyes.

Начало: 25.08.2025 Край: 01.08.2027 Възраст: от 18 г.

China Zhongshan Ophthalmic Center, Sun Yat-sen University NCT07126470

Recruiting Phase 1

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue +15

This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Many racial and ethnic minorities face additional treatment challenges which may lead to poorer outcomes, however, there are fewer racial and ethnic minorities participating in clinical trials. Zanubrutinib, a type of tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Sonrotoclax works by blocking a protein called B-cell lymphoma-2 (Bcl-2). This protein helps certain types of blood cancer cells to survive and grow. When sonrotoclax blocks Bcl-2, it slows down or stops the growth of cancer cells and causes them to die. Zanubrutinib and sonrotoclax have been shown to be an effective treatment for B-cell cancers. Giving zanubrutinib in combination with sonrotoclax may be effective in treating ethnic and racial minorities with relapsed or refractory B-cell non-Hodgkin lymphoma.

Начало: 25.08.2025 Край: 31.01.2029 Възраст: от 18 г.

United States City of Hope Medical Center NCT06859008

Recruiting

Physical Mobilisation to Acquired Brain Injury Patients in Intensive Care Units: a Prospective Cohort Study

Acute Brain Injury

The objective of this study is to quantify the amount of physical mobilisation provided to patients with moderate to severe acquired brain injury in Scandinavian neuro-ICs, and the association between intensity and duration of mobilisation, physiological data perceived to be related to the safety of high-level mobilisation, and amount of high-level mobilisation during the neuro-ICU stay.

Начало: 25.08.2025 Край: 01.01.2027 Възраст: от 18 г.

Denmark Rigshospitalet, Denmark NCT07548580

Recruiting Phase 2

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Primary Membranous Nephropathy

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN

Начало: 25.08.2025 Край: 01.10.2027 Възраст: 18–75 г.

Argentina, Brazil, Georgia +3 Climb Bio, Inc. NCT07096843

Recruiting Phase 1/2

A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

Alzheimer Disease

The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.

Начало: 25.08.2025 Край: 30.09.2026 Възраст: 50–85 г.

Austria, Germany NSC-Therapeutics NCT06995573

Recruiting Phase 2

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）

Obesity and Overweight

This is a multicenter, double-blind, randomized, placebo-controlled phase Ⅱ study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of YN-011 in subjects with overweight (27 kg/m2 ≤ BMI \< 30 kg/m2, with at least one comorbidity) or obesity (BMI ≥ 30 kg/m2, with or without comorbidities). The entire study period will consist of a 2-week screening period, a 22-week double-blind treatment period, and a 4-week off-treatment follow-up period

Начало: 25.08.2025 Край: 01.08.2026 Възраст: 18–75 г. Treatment

Australia Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. NCT07114419

1 … 75 76 77 78 79 … 222